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Molecular Mechanisms of 
Peritoneal Dialysis–Induced 
Microvascular Vasodilation
Peritoneal dialysis (PD) solutions dilate microves-
sels by undefined mechanisms. This vasodilation 
directly affects ultrafiltration and solute exchange 
during a PD dwell and is thought to account for the 
variable mass transfer area coefficient for small 
solutes during a glucose-based hypertonic dwell. We 
hypothesized that PD-mediated vasodilation occurs 
by endothelium-dependent mechanisms that involve 
endothelium energy-dependent K+ channels (KATP), 
adenosine A1 receptor activation, and NO release.
We used intravital videomicroscopy to study 3 
levels of microvessels (A1 inflow arterioles about 
100 μm diameter to pre-capillary A3 arterioles 10 – 
15 μm diameter) in the terminal ileum of anesthetized 
rats under control conditions in vivo in a tissue 
bath. Ileum was bathed with hypertonic mannitol or 
2.5% glucose-based PD solution (Delflex: Fresenius 
Medical Care North America, Waltham, MA, U.S.A.) 
with or without topical application of individual or 
combined specific inhibitors of the endothelium-
dependent dilation pathways: NO (L-NMMA), 
prostaglandin I2 (mefenamic acid), endothelium hy-
perpolarizing factor (glibenclamide), and adenosine 
A1 receptor antagonist (DPCPX).
The mannitol and PD solutions induced rapid and 
sustained peritoneal vasodilation whose magnitude 
depended on microvascular level and osmotic sol-
ute. Combined inhibition of endothelium-dependent 
dilation pathways completely abolished the mannitol-
induced hyperosmolality-mediated dilation at all 
microvascular levels, but selectively eliminated the PD 
solution–mediated A3 dilation. The KATP and adenos-
ine receptor antagonists, individually or combined, 
remarkably attenuated dilation in the smaller pre-cap-
illary arterioles; NO inhibition, alone or combined with 
KATP and adenosine receptor antagonists, eliminated 
the PD solution–induced dilation. The cyclooxygenase 
pathway is not involved in PD-induced dilation.
Solutions for PD dilate the visceral perito-
neal microvasculature by endothelium-dependent 
mechanisms, primarily the NO pathway. Adenosine 
receptor–activated NO release and KATP channel-
mediated endothelium hyperpolarization significantly 
contribute to vasodilation in the smaller peritoneal 
pre-capillary arterioles.
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Introduction
The effective capillary surface area available for 
exchange during peritoneal dialysis (PD) determines 
mass solute transport and ultrafiltration. In acute 
PD, this surface area is functionally recruited by the 
pre- to post-capillary resistance ratio that modulates 
the number of perfused capillaries. Changes in the 
resistance ratio are dictated by the prevailing vasoac-
tivity (dilation or constriction) of those microvessels.
Numerous publications have shown that PD 
solutions dilate both the visceral and the parietal 
microvascular beds (1–5). The general consensus is 
that hyperosmolality, low pH, and glucose degrada-
tion products (GDPs) are the components that give 
PD solutions their vasoactive properties; however, 
ranking the vasoactive potencies of those components 
remains controversial (2–5). In addition, no studies 
are specifically investigating the molecular mecha-
nisms of PD solution–induced vasoactivity.
White and colleagues (6,7) demonstrated that 
glucose-based PD solutions reverse a NO-inhibition-
mediated vasoconstriction of the mesenteric arterioles 
and prevent venular leukocyte adhesion by a NO syn-
thase (NOS)–independent pathway. Steenburgen and 
Bolen (8) showed that hyperosmolar sodium solutions 
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perfused into the intestinal lymph produce vasodila-
tion of submucosal arterioles through a mechanism 
partially mediated by a hyperosmolality-induced 
release of NO. Similarly, intravenous infusion of 
hypertonic galactose or mannitol solutions in pigs 
increased baseline hepatic blood flow, presumably by 
a mechanism attributed to osmotic stress (9). Other 
in vitro studies have found that suffusion of isolated, 
cannulated, and pressurized skeletal muscle arterioles 
with solutions made hypertonic by the addition of 
various osmotic solutes produces equal arteriolar dila-
tion. That hyperosmolality-driven dilation was caused 
by endothelium-mediated mechanisms independent 
of the NOS or cyclooxygenase pathways, and was 
abolished by glibenclamide, an ATP-sensitive potas-
sium channel (KATP) inhibitor (10). Similar results 
were obtained in coronary arterioles perfused ex vivo 
with either hypertonic glucose or sucrose solutions. 
In those vessels, only glibenclamide caused attenu-
ation of the hypertonic solution–mediated vascular 
relaxation; in contrast, the inhibition of other potas-
sium channels had no effect on the hyperosmolality-
induced vascular reactivity (11,12).
Hein and colleagues (13,14) examined the direct 
effect of lactate or adenosine on retinal vascular 
tone. Lactate produces its microvascular effects 
predominantly through NO release that activates 
guanylyl cyclase, with subsequent opening of KATP 
for vasodilation. Adenosine dilates the microvascu-
lature by activation of adenosine receptor subtypes 
and subsequent secondary release of NO and opening 
of KATP. This adenosine-mediated mechanism was 
confirmed in our recent intravital microscopy study 
of the visceral peritoneal microvasculature (5). In 
that study, we demonstrated that topical application 
of an isotonic glucose solution to the small intestine 
produces time-dependent vasodilation, preferentially 
of the smaller pre-mucosal precapillary arterioles 
(5). That vasodilation was not observed when the 
intestine was topically exposed to isotonic mannitol 
solution. Subsequently, we showed that this glucose-
specific preferential vasodilation can be completely 
abolished by specific inhibition of the adenosine A1 
receptor subtypes (5).
Collectively, our data and the cited literature sug-
gest that the vasoactivity produced by PD solutions 
must occur by endothelium-dependent mechanisms, 
which are largely triggered by hyperosmolality. We 
therefore hypothesized that acute exposure of the 
visceral peritoneal microvasculature to glucose-
based PD solutions produces vasodilation of the 
visceral peritoneal microvasculature by endotheli-
um-dependent mechanisms that involve at least two 
signaling pathways:
• Hyperpolarization secondary to hyperosmolality-
induced activation of a glibenclamide-sensitive 
K channel (K+ATP)
• NO release secondary to energy-dependent 
intracellular glucose uptake and activation of 
adenosine receptors
Methods
General animal care and surgery
All animal care and experimental procedures con-
formed to the Principles of Laboratory Animal Care 
from the National Society for Medical Research and 
the Guide for the Care and Use of Laboratory Ani-
mals from the U.S. National Academy of Sciences as 
published by the National Institutes of Health (revised 
1987) and were approved in advance by the institu-
tional animal care and use committees of Hamad 
Medical Corporation and Qatar University.
Experiments were performed on rats (200 – 210 g) 
that had fasted overnight. Anesthesia was induced 
with intraperitoneal pentobarbital (60 mg/kg) and 
maintained with supplemental subcutaneous injections 
as needed to maintain a surgical plane of anesthesia. 
A rectal probe and servo-controlled heating pad were 
used to maintain body temperature at 37 ± 0.5°C. 
Surgery was carried out after loss of the blink and 
withdrawal reflexes. Tracheostomy was performed to 
reduce airway resistance, and the animals were allowed 
to spontaneously breathe room air. The right femoral 
artery was cannulated with a PE-50 catheter to provide 
continuous monitoring and online recording of arterial 
blood pressure.
Bathing solutions
All chemicals were purchased from the Sigma 
Chemical Company (St. Louis, MO, U.S.A.). The 
intestinal segment was continuously bathed during 
tissue preparation and equilibration with a non-
vasoactive (glucose-free) modified Krebs solution 
(solution A) that contained 6.92 g/L sodium chlo-
ride, 0.44 g/L potassium chloride, 0.37 g/L calcium 
chloride, and 2.1 g/L sodium bicarbonate at a pH of 
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7.4 and an osmolality of 285 mOsm/L. To separate 
hyperosmolality from other potential vasoactive 
components of conventional PD solutions, a hy-
pertonic 5% mannitol solution was studied. Man-
nitol was added to the Krebs solution to yield a 
final osmolality of 560 mOsm/L and a pH of 7.4. A 
conventional 2.25% dextrose-based heat-sterilized 
dialysis solution (Delflex: Fresenius Medical Care 
North America, Waltham, MA, U.S.A.) that contains 
5.67 g/L sodium chloride, 3.92 g/L sodium lactate, 
0.257 g/L calcium chloride, and 0.152 g/L magne-
sium chloride at a pH of 5.5 and an osmolality of 
398 mOsm/L served as a second test solution. All 
solutions were filter-sterilized and warmed to 37°C 
before use.
The two hypertonic solutions with differing 
compositions and levels of osmolality were used in 
the present study by design. The hypertonic mannitol 
solution addressed two important issues:
• Isolation of hyperosmolality from other potential 
vasoactive components of PD solution (pH, lac-
tate, GDPs), because hyperosmolality is the major 
vasoactive component shared by conventional 
and new PD solutions (15)
• Total exclusion of the solute (which is metaboli-
cally inert) from cells, thereby allowing for exclu-
sion of the intracellular solute uptake signaling 
pathway, which is then unique for glucose (5)
Drugs
All chemicals were purchased from the Sigma 
Chemical Company unless otherwise indicated. The 
chemicals included KATP inhibitor (glibenclamide, 
20 μmol/L); adenosine A1 receptor antagonist 
(DPCPX, 200 nmol/L); NOS inhibitor (L-NMMA, 
100 μmol/L); cyclooxygenase inhibitor (mefenamic 
acid, 40 μmol/L).
The effective concentration of each of the specific 
antagonists used in the present study was determined 
from various sources, including the manufacturer, 
published data, and our previous studies. The DPCPX 
concentration used here and in our earlier studies 
represented at least 3 times the 50% effective inhibi-
tory concentration for the adenosine A1 receptor as 
determined by information provided by the manu-
facturer. Acetylcholine hydrobromide and sodium 
nitroprusside were used to evaluate the integrity of the 
vascular endothelium and to determine the maximal 
endothelium-independent response at the end of each 
experimental protocol. In the tissue bath, isoproter-
enol was topically applied to retard peristalsis without 
unwanted effects on the contractile machinery of the 
vascular smooth muscle (16).
Experimental procedure
The peritoneal cavity was exposed through a midline 
abdominal incision (1.5 cm), and a 2-cm to 3-cm 
segment of the terminal ileum was gently withdrawn 
from the peritoneal cavity with its neurovascular 
supply intact. Using electrocautery, the segment was 
opened along its antimesenteric border. The enteric 
contents were gently removed from the mucosal sur-
face, and the animal was positioned on a specially-
designed polyurethane board. Using 4-0 silk sutures, 
the opened ileum was suspended, serosal side up, over 
a viewing port in a tissue bath. The non-vasoactive 
bathing solution was maintained at 37°C and was 
bubbled with nitrogen and carbon dioxide to maintain 
a pH of 7.4. Isoproterenol was added to the bathing 
solution in a very dilute concentration (0.01 μg/mL) 
to retard peristalsis. This dose of isoproterenol was 
orders of magnitude below the threshold at which 
vascular smooth muscle tone is altered (16).
The animal board was positioned on the stage of 
a trinocular microscope for direct in vivo intravital 
microscopy. Microvascular images were transmit-
ted through the microscope to a photodiode array 
in an optical Doppler velocimeter (Microcirculation 
Research Institute, Texas A&M University, College 
Station, TX, U.S.A.) to measure centerline red blood 
cell velocity for the calculation of blood flow (in 
nanoliters per second) in the intestinal A1 inflow 
arteriole (FA1):
FA1 = (V / 1.6) (πr2) (0.001),
in which V is the centerline red blood cell veloc-
ity (in millimeters per second), r is the A1 arteriole 
radius (in micrometers), 1.6 is a correction factor that 
converts centerline velocity to average cross-sectional 
velocity, and 0.001 is a conversion factor to express 
flow in nanoliters per second (17). This equation as-
sumes a parabolic flow velocity and a circular conduit. 
Studies have identified 1.58 – 1.60 as the ideal cor-
rection factor for a wide range of microvessels (17).
The microvascular images were then transmitted 
to a digital camera (Model K-P D51: Hitachi Denshi, 
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Tokyo, Japan), which provided 30 images per second 
to a computer. The digitalized microvascular images 
were stored as streamline video in the computer hard 
drive for later measurement of microvascular diam-
eters with calipers.
Criteria for an acceptable microvascular prepara-
tion during intravital microscopy included a baseline 
mean arterial pressure greater than 90 mmHg, a 
centerline red blood cell velocity in a first-order ar-
teriole of more than 20 mm/s, and active vasomotion 
in the intestinal pre-mucosal A3 arterioles. We used a 
standard nomenclature for the intestinal microvessels 
(Figure 1), as originally described by Bohlen and Gore 
(16). Briefly, first-order arterioles (A1) arise from a 
mesenteric arcade artery to traverse the mesenteric 
border of the bowel wall and then penetrate through 
the muscle layers to the submucosal layer. In the sub-
mucosal layer, second-order arterioles (A2) arise from 
the first-order arterioles to run along the longitudinal 
axis of the bowel. First and second-order venules (V1, 
V2) parallel the first and second-order arterioles. The 
A2 arterioles give rise to branching second-order ar-
cade vessels as well as to smaller third-order arterioles 
(A3). The A3 vessels branching at a right angle from 
the A2 arterioles are termed proximal pre-mucosal 
A3 arterioles; they eventually form distal A3 (dA3) 
arterioles, which terminate in the mucosa as central 
villus arterioles.
figure 1 Anatomy of the intestinal (terminal ileum) microcircula-
tion of the visceral peritoneum. A1 = first-order inflow arteriole; 
V1 = first-order venule; A2 = branching second-order arteriole; 
V2 = second-order venule; A3 = pre-mucosal third-order arteriole.
Experimental protocol and measurements
Figure 2 depicts the timeline of the experimental 
protocol. After surgical preparation, 40 minutes were 
allowed for the intestinal segment to equilibrate in 
the tissue bath. During that time, the segment was 
continuously bathed in the non-vasoactive Krebs solu-
tion. Blood pressure, heart rate, rectal and bath tem-
peratures, and bath pH were continuously monitored 
(Digi-Med Signal Analyzers: Micro-Med, Louisville, 
KY, U.S.A.) and recorded every 5 minutes during the 
equilibration period.
Microvascular data consisted of A1, pA3, and 
dA3 arteriolar diameters and centerline red blood 
cell velocity in the inflow A1 arteriole. Baseline 
measurements were considered valid when the 
variability between two successive measurements 
within a 10-minute interval was less than 5%. After 
baseline measurements, the designated inhibitor was 
added topically to the non-vasoactive Krebs solution 
in the tissue bath for 10 minutes, and microvascular 
diameters and flow data were recorded. Next, the 
non-vasoactive Krebs solution was aspirated from the 
tissue bath, and the test solution with the designated 
inhibitor was instilled into the tissue bath according 
to protocol. Microvascular data points were first mea-
sured at 5 minutes after addition of the test solution 
and then at 20-minute intervals during the subsequent 
60 minutes. At the conclusion of the experiment, one 
dose of acetylcholine hydrobromide (10–4 mol/L) was 
topically administered in the tissue bath, and micro-
vascular data were measured at 1-minute intervals 
for 10 minutes to assess endothelial cell function 
and endothelium-dependent receptor-dependent va-
sodilation after acetylcholine hydrobromide. Finally, 
a single dose of sodium nitroprusside (10–4 mol/L) 
was topically administered in the tissue bath to as-
sess the endothelium-independent maximal dilation 
capacity. It should be emphasized that no sequential 
addition of solutions or inhibitors was given in any 
anesthetized animal.
Experimental groups
The experimental groups were assigned to assess 
all 4 endothelium-dependent dilation pathways for 
individual antagonists or combinations thereof:
• NO pathway
• Endothelium-dependent hyperpolarizing factor 
(EDHF)
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• Cyclooxygenase pathway (PGI2)
• Adenosine signaling pathway (because the ad-
enosine signaling pathway is unique for glucose, 
the specific adenosine A1 receptor antagonist 
DPCPX was not used individually in the man-
nitol series)
Animals were randomly assigned (7 per group) 
to a mannitol series (6 groups) or a PD solution series 
(6 groups):
• Group I: 5% mannitol
• Group II: 5% mannitol plus glibenclamide
• Group III: 5% mannitol plus glibenclamide plus 
DPCPX
• Group IV: 5% mannitol plus glibenclamide plus 
L-NMMA
• Group V: 5% mannitol plus glibenclamide plus 
DPCPX plus L-NMMA
• Group VI: 5% mannitol plus L-NMMA
• Group VII: PD solution
• Group VIII: PD solution plus glibenclamide
• Group IX: PD solution plus DPCPX
• Group X: PD solution plus glibenclamide plus 
DPCPX
• Group XI: PD solution plus glibenclamide plus 
DPCPX plus mefenamic acid
• Group XII: PD solution plus glibenclamide plus 
DPCPX plus L-NMMA
• Group XIII: PD solution plus L-NMMA
Data analysis and statistics
All data are presented as mean ± standard error of the 
mean. Microvascular diameter data are normalized 
and presented as percentage change from baseline. 
Percentage change of the vessel diameter from base-
line was assessed by one-way analysis of variance, 
and the Dunnett multiple-range test was used to 
evaluate change from baseline in the same animal. 
Two-way analysis of variance and Bonferroni post-
tests were used to assess the relationship between 
vascular reactivity and arteriolar type, and to evaluate 
the effects of inhibition of the endothelium-dependent 
dilation pathways and vascular response. Statistical 
significance was set a priori for the probability of a 
type I error at p < 0.05.
Results
Baseline hemodynamics were not significantly differ-
ent in the experimental groups (Table I). Instillation of 
PD solution alone or with the inhibitors in the tissue 
bath did not cause any significant change in mean 
arterial pressure from baseline in any of the animals 
investigated in the present study (data not shown). 
Intestinal A1 blood flow increased significantly in 
concert with the vessel diameter change produced by 
the test solution or by the designated endothelium-
dependent pathway inhibition (Figure 3). Venous 
outflow in the V1 venule mirrored the changes in the 
corresponding A1 arteriolar flow (data not shown).
Study I: mannitol series
In the first series of experiments, mannitol was 
used as an osmotic solute to isolate and assess the 
molecular mechanisms of hyperosmolality-induced 
vasodilation, without the potential confounding 
vascular effects from glucose, low pH, lactate, and 
GDPs. The hypertonic mannitol solution produced 
figure 2 Timeline of the experimental protocol. Bold arrowheads mark the times at which microvascular images and hemodynamic 
data were acquired. BL = baseline measurements; ACh = acetylcholine; SNP = sodium nitroprusside.
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instantaneous and sustained vasodilation of the large 
A1 arteriole [10.7% ± 1.2%, n = 7, p < 0.001 vs. base-
line; Figure 4(A)]. Inhibition of NO had no effect on 
the A1 mannitol-induced dilation [Figure 4(A); n = 7, 
p > 0.1]; however, the dilation was partially attenuated 
by KATP inhibition (–36.4% ± 1.2%, n = 7, p < 0.05) 
and by combined adenosine A1 receptor and KATP 
inhibition (–30.4% ± 2.1%, n = 7, p < 0.05). In addition, 
mannitol-mediated dilation was markedly attenuated 
by combined KATP and NO inhibition (–72.2% ± 3.4%, 
table i Summary of baseline values
Group Pathways and antagonists MAP
(mmHg)
Diameter (μm) A1 flow
(nL/s)
A1 pA3 dA3
I 5% Mannitol (no inhibitor) 115±4 76.1±5.6 15.0±0.5 10.1±0.4 578±11
II KATP (glibenclamide) 113±5 79.2±5.0 13.8±0.7 9.8±0.3 585±12
III KATP (glibenclamide) + AdoA1 (DPCPX) 114±4 89.0±2.6 13.4±0.7 10.1±0.7 666±6
IV KATP (glibenclamide) + NO (L-NMMA) 110±5 85.1±3.9 14.7±0.5 11.0±0.6 587±10
V KATP (glibenclamide) + A1 (DPCPX) + NO (L-NMMA) 114±6 98.2±2.0 13.3±0.5 9.0±0.4 763±6
VI NO (L-NMMA) 117±3 75.6±6.5 14.3±0.7 10.8±0.5 463±10
VII 2.5% Delflex (no inhibitor) 117±4 85.1±4.9 14.2±0.8 9.7±0.5 595±9
VIII KATP (glibenclamide) 112±5 88.1±2.8 15.1±0.5 10.9±0.3 587±4
IX AdoA1 (DPCPX) 116±8 91.5±3.6 12.1±0.7 9.1±0.8 550±6
X KATP (glibenclamide) + AdoA1 (DPCPX) 116±8 95.3±3.6 13.1±1.1 9.5±1.0 654±8
XI KATP (glibenclamide) + AdoA1 (DPCPX) + cyclooxygenase (MA) — 98.2±4.9 12.9±0.7 9.2±0.2 683±8
XII KATP (glibenclamide) + A1 (DPCPX) + NO (L-NMMA) 117±2 90.3±4.1 13.2±0.7 9.4±0.7 552±5
XIII NO (L-NMMA) 109±5 71.8±4.0 15.4±0.5 10.2±0.5 457±7.0
MAP = mean arterial pressure; A1 = inflow arteriole; pA3 = proximal pre-mucosal arteriole; dA3 = distal pre-mucosal arteriole; KATP = 
endothelium energy-dependent K+ channels; AdoA1 = adenosine A1 receptor activation; DPCPX = dipropylcyclopentylxanthine; 
L-NMMA = NG-monomethyl-l-arginine; MA = mefenamic acid.
figure 3 Intestinal A1 (inflow arteriole) blood flow. (A) Group I: 5% mannitol, no antagonists; Group II: 5% mannitol plus glibenclamide 
(a specific ATP-dependent potassium channel blocker); Group III: 5% mannitol plus glibenclamide plus DPCPX (an adenosine A1 re-
ceptor antagonist); Group IV: 5% mannitol plus glibenclamide plus L-NMMA (NG-monomethyl-l-arginine, a NO inhibitor); Group V: 
5% mannitol plus glibenclamide plus DPCPX plus L-NMMA; Group VI: 5% mannitol plus L-NMMA. (B) Group VII: 2.5% glucose 
peritoneal dialysis (PD) solution (Delflex: Fresenius Medical Care North America, Waltham, MA, U.S.A.), no antagonists; Group VIII: 
Delflex plus glibenclamide; Group IX: Delflex plus DPCPX; Group X: Delflex plus glibenclamide plus DPCPX; Group XI: Delflex plus 
glibenclamide plus DPCPX plus mefenamic acid (a cyclooxygenase pathway inhibitor); Group XII: Delflex plus glibenclamide plus 
DPCPX plus L-NMMA; Group XIII: Delflex plus L-NMMA. *p < 0.001 compared with baseline by two-way analysis of variance and 
Bonferroni posttest.
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n = 7, p < 0.01) and completely abolished by combined 
adenosine A1 receptor, KATP, and NO inhibition 
(–97.6% ± 1.6%, n = 7, p < 0.001).
Hypertonic mannitol-mediated vasodilation of 
the smaller pA3 and dA3 pre-mucosal precapillary 
arterioles was 21.7% ± 2.0% and 26.5% ± 2.2% from 
baseline [Figure 4(B,C)], which is double the magni-
tude of the dilation seen in the larger inflow arterioles, 
suggesting a dependency of hyperosmolality-induced 
vascular reactivity on vessel level. Inhibition of only 
KATP caused significant attenuation of mannitol-
induced vasodilation (–48.5% ± 1.6% and –51.1% ± 
1.2% in the pA3 and dA3 arterioles respectively, 
n = 7, p < 0.001). Similar attenuation of mannitol-
induced dilation in the pA3 (–66.2% ± 1.4%, n = 7, 
p < 0.001) and dA3 arterioles (–63.3% ± 1.7%, n = 7, 
p < 0.001) was obtained with combined inhibition of 
KATP and the adenosine A1 receptor. However, NO 
inhibition alone or in combination with inhibition of 
KATP or adenosine A1 receptor completely abolished 
mannitol-mediated dilation in the pA3 and dA3 pre-
mucosal precapillary arterioles alike (n = 7, p < 0.001).
Study II: PD solution series
The 2.5% glucose-based heat-sterilized PD solution 
produced instantaneous and sustained vasodilation at 
all intestinal visceral peritoneal microvascular levels 
[Figure 5, showing the (A) A1, (B) pA3, and (C) dA3 
intestinal arteriole results]. That dilation was double 
the magnitude of the mannitol-induced dilation (Fig-
ure 4) at all arteriolar levels and was more remarkable 
in the smaller pre-mucosal precapillary arterioles.
Those findings suggest that the PD solution has 
vasoactive components other than hyperosmolality 
and that the magnitude of the vasoactivity depends 
on vessel level. In the larger inflow arterioles, PD 
solution produced an average dilation of 18.5% ± 
3.2% from baseline (n = 7, p < 0.01). That dilation 
was not affected by adenosine A1 receptor inhibition 
(–14.3% ± 3.6%, n = 7, p > 0.05). However, inhibition 
of NO or KATP attenuated the dilation by –45.2% ± 
3.2% (n = 7, p < 0.05) and –50.0% ± 2.2% (n = 7, 
p < 0.05) respectively. Combined inhibition of the 
adenosine A1 receptor, KATP, and NO pathways or of 
adenosine A1 receptor and KATP attenuated the PD 
solution–induced dilation in the inflow A1 arteriole 
by –60.0% ± 2.6% and –61.6% ± 3.2% respectively 
(n = 7, p < 0.05), which is similar to the attenuation 
produced by NO or KATP inhibition.
figure 4 Effects of endothelium-dependent antagonists on mannitol-
induced vasodilation in (A) inflow (A1) arterioles, (B) proximal pre-
mucosal (pA3) arterioles, and (C) distal pre-mucosal (dA3) arterioles. 
Group I (solid circles): 5% mannitol, no antagonists; Group II (open 
circles): 5% mannitol plus glibenclamide (a specific ATP-dependent 
potassium channel blocker); Group III (open squares): 5% mannitol 
plus glibenclamide plus DPCPX (an adenosine A1 receptor antagonist); 
Group IV (open inverted triangles): 5% mannitol plus glibenclamide 
plus L-NMMA (NG-monomethyl-l-arginine, a NO inhibitor); 
Group V (open diamonds): 5% mannitol plus glibenclamide plus 
DPCPX plus L-NMMA; Group VI (open triangles): 5% mannitol 
plus L-NMMA. *p < 0.001 compared with the NO inhibitor group 
(Group I). †p < 0.001. §p < 0.05 compared with baseline, by two-way 
analysis of variance and Bonferroni post-test. BL = baseline.
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The PD solution–mediated vasodilation of the 
smaller pA3 and dA3 pre-mucosal precapillary 
arterioles was 35.3% ± 3.2% and 46.1% ± 5.1% (n = 
7, p < 0.001) from baseline [Figure 5(B,C)], which 
is approximately twice the magnitude of the dila-
tion seen in the larger inflow arterioles, suggesting 
dependency of the PD solution–induced vascular 
reactivity on vessel level. Inhibition of only KATP 
caused significant attenuation of PD solution–in-
duced vasodilation to –64.6% ± 3.6% and –65.9% ± 
3.2% in the pA3 and dA3 arterioles respectively (n = 
7, p < 0.001). Selective inhibition of the adenosine 
A1 receptor significantly attenuated the PD solution–
mediated dilation by –37.8% ± 3.2% and –59.3% ± 
4.4% in the pA3 and dA3 arterioles respectively. 
Marked attenuation of PD solution–induced dilation 
in the pA3 (–66.7% ± 2.4%, n = 7, p < 0.001) and 
dA3 arterioles (–80.5% ± 3.7%, n = 7, p < 0.001) 
was obtained with combined KATP and adenosine 
A1 receptor inhibition.
Addition of cyclooxygenase inhibition to the 
combined blockade of the KATP and adenosine 
A1 receptor pathways caused no further attenu-
ation of the PD solution–mediated dilation at any 
microvascular level, but selective inhibition of the 
NO pathway alone completely abolished the PD 
solution–mediated precapillary A3 dilation (n = 
7, p < 0.001). Similarly, NO inhibition, alone or 
in combination with inhibition of the KATP and 
adenosine A1 receptor pathways, completely abol-
ished the PD solution–mediated dilation in the pA3 
and dA3 pre-mucosal precapillary arterioles alike 
(n = 7, p < 0.001).
Study III: isotonic Krebs series
In a separate series of control experiments, the 
intestinal visceral peritoneal microvasculature 
was bathed with a non-vasoactive isotonic Krebs 
solution, and microvascular diameter and f low 
were assessed after inhibition of the NO pathway 
or combined blockade of the NO, KATP, and ad-
enosine A1 receptor subtypes. As seen in Figure 6, 
NO inhibition alone or in combination with inhibi-
tion of KATP and adenosine A1 receptor—and in 
the absence of the vasoactive components of PD 
solution—produced marginal vasoconstriction of 
the inflow A1 and precapillary A3 arterioles. This 
vasoconstriction produced a modest decline in A1 
blood flow (n = 7, p < 0.05).
figure 5 Effects of endothelium-dependent antagonists on 2.5% 
Delflex (conventional peritoneal dialysis solution from Fresenius 
Medical Care North America, Waltham, MA, U.S.A.)–induced 
dilation in (A) inflow (A1) arterioles, (B) proximal pre-mucosal (pA3) 
arterioles, and (C) distal pre-mucosal (dA3) arterioles. Group VII 
(closed circles): Delflex, no antagonists; Group VIII (open circles): 
Delflex plus glibenclamide (a specific ATP-dependent potassium 
channel blocker); Group IX (open inverted triangles): Delflex plus 
DPCPX (an adenosine A1 receptor antagonist); Group X (open 
squares): Delflex plus glibenclamide plus DPCPX; Group XI (half-
closed squares): Delflex plus glibenclamide plus DPCPX plus 
mefenamic acid (a cyclooxygenase pathway inhibitor); Group XII 
(open diamonds): Delflex plus glibenclamide plus DPCPX plus 
L-NMMA (NG-monomethyl-l-arginine, a NO inhibitor); Group XIII 
(open triangles): Delflex plus L-NMMA. *p < 0.001 compared with 
the NO inhibitor group (Group VII). †p < 0.001. §p < 0.05 compared 
with baseline by two-way analysis of variance and Bonferroni 
post-test. BL = baseline.
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Discussion
The present study is the first to define the molecular 
mechanisms of conventional PD solution–induced 
dilation of the visceral peritoneal microvasculature. 
Such dilation is rapid, sustained, and dependent on 
the vascular endothelium. The endothelium signaling 
pathways involved in this dilation are determined 
by the anatomic level of the microvessel in the mi-
crovascular tree. In the larger inflow A1 arterioles 
(about 100 μm in diameter), NO and KATP channels 
are moderately involved in PD solution–mediated 
vasodilation, and the contribution of the adenosine 
A1 receptors is minimal. In the smaller pre-mucosal 
precapillary pA3 arterioles (about 15 μm in diameter) 
and the dA3 arterioles (about 9 μm in diameter), the 
NO pathway accounts for all of the PD solution–medi-
ated vasoactivity. Those findings are not surprising, 
because depending on the vascular bed, microves-
sels of similar size are well known to use different 
mechanisms for endothelium-dependent regulation of 
vascular tone (18). Similarly, the relative contributions 
of agonist-stimulated NO and EDHF to endothelium-
dependent relaxation appears to vary by sex (19), by 
arteriolar size within the same vascular bed (20), and 
by vascular bed (18,21,22).
Inflow arteriole reactivity
Intestinal visceral inflow arterioles (70 – 100 μm) 
are first-order (A1) branches from the mesenteric 
arcade (16). As shown in the present study, mannitol 
solution and PD solution both produced rapid and 
sustained vasodilation in A1 arterioles. Compared 
with downstream dilation, the A1 arteriole dilation 
was significantly less in magnitude. The A1 arteriole 
dilation was also greater with PD solution than with 
hypertonic mannitol solution despite the remarkably 
greater osmolality of the mannitol solution.
Interpretation of the different results with manni-
tol and with PD solution is based both on physiologic 
principles and on biochemical differences between the 
two solutions. Physiologically, the vascular control 
mechanisms of the larger inflow A1 arterioles are 
quite different from the mechanisms that control 
vascular tone in the smaller downstream precapillary 
arterioles. Intestinal A1 vascular control is predomi-
nantly neurogenic: the neurohormonal reflexes are 
centrally driven through preganglionic sympathetic 
fibers of the intermediolateral area of the spinal cord. 
This neurogenic input to the large mesenteric arteries 
and smaller A1 arterioles is primarily sympathetic, 
with the α-adrenergic (vasoconstriction) influence 
figure 6 Microvascular diameters of visceral intestine (isotonic Krebs series). §p < 0.05 compared with baseline by two-way analysis 
of variance and Bonferroni post-test. BL = baseline; A1 = inflow arteriole; L-NMMA = NG-monomethyl-l-arginine, a NO inhibitor; 
pA3 = proximal pre-mucosal arteriole; dA3 = distal pre-mucosal arteriole; Glib = glibenclamide, a specific ATP-dependent potassium 
channel blocker; dpcpx = an adenosine A1 receptor antagonist.
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predominating over the β-adrenergic (vasodilation) 
influence (23,24). In contrast, vascular control of 
the smaller intestinal A3 precapillary arterioles is 
exclusively local, using metabolic and paracrine 
mechanisms (25).
Biochemically, conventional glucose PD solu-
tion has vasoactive components other than hyper-
osmolality (15) and a dilation mechanism that is 
unique to glucose and therefore not available to 
mannitol. However, as demonstrated in the present 
studies, the fractional contribution of the adenosine 
pathway to the PD solution–induced A1 dilation 
is particularly trivial, because there is nearly no 
distribution and expression of adenosine receptors 
in the A1 arterioles (26).
In recent studies, we demonstrated that lactate (the 
buffer anion system of PD solution) produces a rapid 
and transient pH-dependent submaximal dilation in 
the intestinal visceral peritoneal microvasculature. 
Glucose degradation products also contribute to the 
dilation (5,15). Lactate at low pH and GDPs are both 
components of the Delflex solution but not of the man-
nitol solution used in the present study. Those differ-
ences explain the difference in the magnitude of A1 
dilation between the mannitol and Delflex solutions.
Precapillary arteriole reactivity
Intestinal visceral precapillary A3 arterioles (10 – 
15 μm) are third-order branches from the second-
order transition A2 arterioles (16). Vascular tone 
regulation of these small precapillary arterioles 
is exclusively autoregulatory and locally derived 
through metabolic and paracrine mechanisms 
within the microenvironment (25). The vasoactivity 
of PD solution is attributed to its hyperosmolality, 
glucose, lactate, and low pH (1–3,5). Those vasoac-
tive components of PD solution must exert their 
vascular effects through metabolic and paracrine 
pathways. The mannitol series in the present study 
was designed to selectively isolate hyperosmolality 
from other vasoactive components of PD solution. 
Results from the mannitol series confirmed that 
hyperosmolality is the major vasoactive component 
of PD solution and that it exerts its A3 arteriolar dila-
tion effects predominantly through KATP. It is likely 
that hyperosmolality-mediated opening of KATP 
channels is associated with the release of energy 
substrates such as adenosine (27), which explains 
the remarkable attenuation of mannitol-induced 
hyperosmolality-mediated dilation with combined 
inhibition of KATP channels and adenosine A1 re-
ceptors (experimental group III). The magnitude of 
the PD solution–mediated A3 dilation, which was 
double that seen in the A1 arterioles, was markedly 
attenuated by individual paracrine and autocrine 
antagonists. In particular, the NO pathway fully 
accounts for the PD solution–mediated A3 dilation. 
However, the remarkable contribution to precapillary 
A3 vasodilation of the adenosine receptor–stimulated 
NO release mechanism and of the opening of KATP 
was also observed. The PD solution–induced A3 dila-
tion is predominantly caused by hyperosmolality, but 
other vasoactive components of the solution (such as 
lactate, low pH, and GDPs) contributed significantly. 
Data from the present study suggest that NO is the 
second messenger involved in the signal transduction 
pathways for vasodilation caused by all vasoactive 
components of conventional PD solutions.
In the present study, the finding that inhibition 
of the NO pathway completely abolishes the dila-
tion response does not refute the contribution of 
K+ATP and adenosine A1 receptor activation to the 
observed dilation response. The interaction between 
the endothelium-dependent dilation pathways is 
well established in the literature. To summarize, 
hyperosmolality and glucose are well recognized to 
separately affect intercellular calcium (Ca2+) homeo-
stasis and mobilization (28–30). In turn, intracellular 
Ca2+ mobilization is known to activate constitutive 
NOS to generate de novo NO from the endothelial 
cell. In addition, NO is generated by lactate at high 
extracellular H+ concentrations, which is the typical 
microenvironment in the presence of PD solution. 
And yet the intracellular signal transduction of this 
lactate-driven, pH-dependent NO release is still 
undetermined. However, data from studies of the 
small retinal arterioles suggest that lactate uptake by 
vascular cells through monocarboxylate transport-
ers causes retinal arteriolar dilation predominantly 
by stimulation of NOS and subsequent activation of 
guanylyl cyclase and cyclase/cGMP signaling that 
triggers opening of KATP channels for vasodilation 
(31). Furthermore, NO is also produced after active 
glucose transport into cells, which results in genera-
tion of adenosine (32,33). Generated adenosine binds 
to its G-protein-coupled receptor, which activates 
adenylate cyclase to increase levels of cAMP. The 
cAMP mobilizes Ca2+, which activates constitutive 
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NO release from endothelial cells and causes opening 
of KATP channels (13). For the endothelium-derived 
NO to elicit vasodilation, NO diffuses to the vascular 
smooth muscle to activate guanylate cyclase and re-
lease soluble cGMP. There are two pathways by which 
cGMP causes vascular smooth muscle relaxation:
• cGMP phosphorylates and activates KATP to 
elicit vasodilation secondary to cell membrane 
hyperpolarization.
• Kinase activation by cGMP elicits relaxation 
directly by lowering Ca2+.
In control studies, Delf lex PD solution was 
instilled into the peritoneal cavity while the small 
segment of the terminal ileum in the tissue bath con-
tinued to be bathed with the non-vasoactive isotonic 
Krebs solution. Surprisingly, no change was observed 
in the ileal microvascular diameter at any level. 
Those observations clearly demonstrate that, for PD 
solution–mediated dilation to occur, contact must be 
established between the intraperitoneal PD solution 
and the tissue. Our earlier studies demonstrated that, 
during the first hour of a dwell, a large intraperito-
neal fill volume makes contact with only about 40% 
of the anatomic peritoneum (34). The suggestion is 
that, during conditions of peritoneal transport stud-
ies in small, quiescent, anesthetized animals, a small 
anatomic peritoneal surface area (about 40%—which 
includes a relatively larger effective vascular surface 
area produced by vasodilation) accounts for the high 
clearance of small solutes during the initial phase of a 
dwell (0 – 30 minutes). The data also imply that, dur-
ing short dwells, a larger anatomic peritoneal surface 
area (about 60% of the anatomic peritoneum) that 
is not in contact with the PD solution encompasses 
a much larger microvascular area that, in effect, 
remains a potential site for dialysis enhancement. 
Potential clinical support for those hypotheses is 
obtained from a comparison of automated PD and of 
long dwells with icodextrin solution. Although the 
mechanisms of water removal are different in those 
PD modalities, relatively smaller contact and vascu-
lar areas are probably used in automated PD than in 
icodextrin dwells.
Conclusions
Peritoneal dialysis solutions produce instanta-
neous and sustained vasodilation of the visceral 
peritoneal microvasculature. The magnitude of the 
dilation response depends on vessel level and is 
mediated by endothelium-dependent mechanisms, 
primarily the NO pathway. The NO release result-
ing from adenosine receptor activation and KATP 
channel-mediated endothelium hyperpolarization 
significantly contribute to vasodilation in the 
smaller precapillary arterioles.
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